Johnson & Johnson (NYSE:JNJ) Shares Purchased by Cora Capital Advisors LLC

Cora Capital Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,448 shares of the company’s stock after acquiring an additional 185 shares during the quarter. Cora Capital Advisors LLC’s holdings in Johnson & Johnson were worth $540,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Massachusetts Wealth Management boosted its holdings in shares of Johnson & Johnson by 4.2% during the third quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock worth $2,508,000 after purchasing an additional 650 shares during the last quarter. Apeiron RIA LLC boosted its stake in Johnson & Johnson by 4.0% in the 3rd quarter. Apeiron RIA LLC now owns 3,800 shares of the company’s stock worth $592,000 after buying an additional 145 shares during the last quarter. Chronos Wealth Management LLC grew its holdings in Johnson & Johnson by 1.5% in the 3rd quarter. Chronos Wealth Management LLC now owns 34,963 shares of the company’s stock valued at $5,445,000 after buying an additional 506 shares during the period. Connecticut Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 46.6% during the 3rd quarter. Connecticut Wealth Management LLC now owns 18,320 shares of the company’s stock worth $2,853,000 after acquiring an additional 5,825 shares during the period. Finally, TFG Advisers LLC boosted its position in shares of Johnson & Johnson by 0.4% in the third quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock worth $2,855,000 after acquiring an additional 67 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.4 %

JNJ stock opened at $149.27 on Friday. The firm has a fifty day moving average price of $154.44 and a two-hundred day moving average price of $155.08. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.91. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The firm has a market cap of $359.70 billion, a price-to-earnings ratio of 9.31, a PEG ratio of 2.49 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter last year, the company earned $2.68 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, April 15th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada reduced their price objective on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, Bank of America dropped their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Insider Buying and Selling

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which is available at this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.